MedTrace Logo

Phase III Cat-PAD Follow-on Study

NCT02040844 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 430

Last updated 2018-06-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the continued effectiveness and safety of Cat-PAD in cat allergic subjects for up to five years after the start of administration of treatment. The study is an optional follow-up study to a phase III double-blind, placebo controlled, Cat-PAD study; no further investigational product is administered.

Conditions

  • Cat Allergy

Interventions

DRUG

Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]

DRUG

Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]

DRUG

Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]

Sponsors & Collaborators

  • Circassia Limited

    lead INDUSTRY

Principal Investigators

  • Jörg Kleine-Tebbe, MD · Clinical Research Center for Dermatology, Allergy & Asthma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2017-05-31
Completion
2017-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02040844 on ClinicalTrials.gov